Back
Entrada Therapeutics 10K Form
Sell
24
TRDA
Entrada Therapeutics
Last Price:
$9.87
Seasonality Move:
1.7%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive TRDA News And Ratings
See the #1 stock for the next 7 days that we like better than TRDA
TRDA Financial Statistics
Sales & Book Value
| Annual Sales: | $210.8M |
|---|---|
| Cash Flow: | $-32.2M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $11.41 |
| Price / Book: | 0.89 |
Profitability
| EPS (TTM): | 1.91000 |
|---|---|
| Net Income (TTM): | $65.6M |
| Gross Margin: | -- |
| Return on Equity: | 18.3% |
| Return on Assets: | 12.42% |
Entrada Therapeutics Earnings Forecast
Key Entrada Therapeutics Financial Ratios
-
The Research & Development expenses have been 59.45% of Revenue.
-
The Net Earning history of TRDA is 31.13% of Total Revenues.
-
Per Share Earnings over the last 6 years have been positive in 3 years.
Entrada Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | TRDA |
| Website: | entradatx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 11.15 |
| Quick Ratio: | 10.73 |
Price-to-Earnings
| Trailing P/E Ratio: | 6.06 |
|---|---|
| Forward P/E Ratio: | 0 |
TRDA Technical Analysis vs Fundamental Analysis
Sell
24
Entrada Therapeutics (TRDA)
is a Sell
Is Entrada Therapeutics a Buy or a Sell?
-
Entrada Therapeutics stock is rated a SellThe current Entrada Therapeutics [TRDA] share price is $10.18. The Score for TRDA is 24, which is 52% below its historic median score of 50, and infers higher risk than normal.